Guru Ownership Trend
Guru Analysis for TG Therapeutics, Inc. (TGTX)
TG Therapeutics, Inc. (TGTX), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q2 2026, a total of 7 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $114.18 M.
Top institutional holders include Renaissance Technologies (RenTech) and Cliff Asness.
Institutional sentiment is currently Strongly Bullish. This is evidenced by a $53.08 M net inflow during the quarter.
Recent activity highlights Steven Cohen who opened a new position. Conversely, Joel Greenblatt reduced exposure by 0.6%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q2 2026)
Guru Consensus (Q2 2026)
FAQs for TG Therapeutics, Inc. (TGTX)
Major holders include Renaissance Technologies (RenTech) ($37.32 M), Cliff Asness ($24.3 M), Ray Dalio ($23.62 M). According to the latest reported data, 7 tracked investment managers collectively hold approximately 2.01 M shares.
According to the latest 13F reporting period, sentiment appears Bullish (Net Buying). There was a net inflow of $53.08 M, with 6 managers increasing positions and 1 managers reducing holdings.
During the most recent reporting period, 1 managers trimmed their positions, while 0 fully exited TGTX. The total reported sell value was $14,614.04.
Yes, 3 managers opened new positions in TGTX, and 3 increased their existing holdings. The total reported buy value was $53.09 M.
